Eyenuk, Inc. — SEC Form D Filing

Eyenuk, Inc. filed an SEC Form D on June 22, 2026, reporting $5.61M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
June 22, 2026
Amount reported
$5.61M
Round stage
Series B+
Industry
Medical Devices
Website
https://www.eyenuk.com/us-en/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Millions of patients are at risk for vision loss due to conditions like diabetic retinopathy, age-related macular degeneration, and glaucoma. A major obstacle to preventing blindness from these diseases is ensuring patients undergo annual screening and diagnosis.

Solution

Eyenuk develops an AI eye screening system, EyeArt®, which autonomously detects diabetic retinopathy, age-related macular degeneration, and glaucoma without the need for expert human grading or eye dilation. This system allows for immediate, on-site screening and reporting in under 60 seconds during a patient's regular exam.

Why now

Advances in artificial intelligence and deep learning, coupled with increasing prevalence of chronic diseases like diabetes, create a strong demand for automated, accessible, and high-volume diagnostic tools to prevent blindness.

Verdict

This cleared because it promised a substantial cost reduction and workflow efficiency gain for a mandatory screening, not because it introduced a novel diagnostic capability. Investors were implicitly betting on regulatory acceptance and a swift path to enterprise sales by leveraging existing clinical mandates. The upside was limited by the specialized buyer universe and the necessity of navigating a conservative healthcare procurement process, rather than broad market adoption.

Source: SEC EDGAR Form D filing